dariohealth - DRIO

DRIO

Close Chg Chg %
10.70 0.68 6.36%

Closed Market

11.38

+0.68 (6.36%)

Volume: 48.30K

Last Updated:

Dec 31, 2025, 4:00 PM EDT

Company Overview: dariohealth - DRIO

DRIO Key Data

Open

$10.57

Day Range

10.39 - 11.47

52 Week Range

5.94 - 31.00

Market Cap

$77.02M

Shares Outstanding

6.77M

Public Float

5.28M

Beta

1.05

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$18.03

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

28.63K

 

DRIO Performance

1 Week
 
13.35%
 
1 Month
 
-3.89%
 
3 Months
 
-30.40%
 
1 Year
 
-27.62%
 
5 Years
 
-96.02%
 

DRIO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3
Full Ratings ➔

About dariohealth - DRIO

DarioHealth Corp. is a digital health company which offers a user-centric and multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. DarioHealth serves customers globally. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.

DRIO At a Glance

DarioHealth Corp.
322 West 57th Street
New York, New York 10019
Phone 1-833-914-3796 Revenue 27.04M
Industry Medical Specialties Net Income -30,088,977.00
Sector Health Technology 2024 Sales Growth 32.862%
Fiscal Year-end 12 / 2025 Employees 202
View SEC Filings

DRIO Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.426
Price to Book Ratio 0.419
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -0.824
Enterprise Value to Sales 1.483
Total Debt to Enterprise Value 0.753

DRIO Efficiency

Revenue/Employee 133,861.386
Income Per Employee -148,955.332
Receivables Turnover 5.309
Total Asset Turnover 0.251

DRIO Liquidity

Current Ratio 2.421
Quick Ratio 2.135
Cash Ratio 1.721

DRIO Profitability

Gross Margin 49.064
Operating Margin -210.854
Pretax Margin -164.937
Net Margin -111.276
Return on Assets -27.954
Return on Equity -46.233
Return on Total Capital -29.438
Return on Invested Capital -33.455

DRIO Capital Structure

Total Debt to Total Equity 41.922
Total Debt to Total Capital 29.539
Total Debt to Total Assets 25.396
Long-Term Debt to Equity 33.654
Long-Term Debt to Total Capital 23.713
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Dariohealth - DRIO

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
20.51M 27.66M 20.35M 27.04M
Sales Growth
+170.76% +34.82% -26.41% +32.86%
Cost of Goods Sold (COGS) incl D&A
16.55M 18.00M 14.37M 13.77M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.53M 3.80M 5.22M 8.33M
Depreciation
493.00K (563.00K) 712.00K 2.23M
Amortization of Intangibles
3.04M 4.36M 4.51M 6.10M
COGS Growth
+226.88% +8.77% -20.18% -4.14%
Gross Income
3.96M 9.65M 5.98M 13.27M
Gross Income Growth
+57.70% +143.63% -38.02% +121.71%
Gross Profit Margin
+19.32% +34.91% +29.40% +49.06%
2021 2022 2023 2024 5-year trend
SG&A Expense
79.58M 66.96M 62.05M 70.28M
Research & Development
17.22M 19.65M 20.25M 24.18M
Other SG&A
62.36M 47.31M 41.80M 46.10M
SGA Growth
+145.49% -15.85% -7.34% +13.28%
Other Operating Expense
- - - -
-
Unusual Expense
880.00K 2.95M 4.32M (11.40M)
EBIT after Unusual Expense
(76.49M) (60.26M) (60.38M) (45.62M)
Non Operating Income/Expense
(151.00K) 749.00K 1.66M 1.11M
Non-Operating Interest Income
44.00K 506.00K 1.87M 1.12M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
84.00K 2.68M 645.00K 96.00K
Interest Expense Growth
+71.43% +3,094.05% -75.96% -85.12%
Gross Interest Expense
84.00K 2.68M 645.00K 96.00K
Interest Capitalized
- - - -
-
Pretax Income
(76.73M) (62.19M) (59.36M) (44.60M)
Pretax Income Growth
-160.58% +18.95% +4.54% +24.87%
Pretax Margin
-374.05% -224.87% -291.68% -164.94%
Income Tax
32.00K 4.00K 64.00K (1.85M)
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - 149.00K
-
Income Tax - Deferred - Domestic
- - - (2.00M)
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- 2.24M 4.57M 12.66M
Consolidated Net Income
(76.76M) (59.96M) (54.86M) (30.09M)
Minority Interest Expense
- - - -
-
Net Income
(76.76M) (59.96M) (54.86M) (30.09M)
Net Income Growth
-160.69% +21.89% +8.50% +45.15%
Net Margin Growth
-374.21% -216.80% -269.56% -111.28%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(76.76M) (59.96M) (54.86M) (30.09M)
Preferred Dividends
- - - 2.00M
-
Net Income Available to Common
(78.77M) (59.96M) (54.86M) (30.09M)
EPS (Basic)
-94.9462 -50.7356 -38.6722 -12.2714
EPS (Basic) Growth
+14.48% +46.56% +23.78% +68.27%
Basic Shares Outstanding
829.59K 1.18M 1.42M 2.45M
EPS (Diluted)
-94.9462 -50.7356 -38.6722 -12.2714
EPS (Diluted) Growth
+14.48% +46.56% +23.78% +68.27%
Diluted Shares Outstanding
829.59K 1.18M 1.42M 2.45M
EBITDA
(72.09M) (53.51M) (50.84M) (48.68M)
EBITDA Growth
-144.81% +25.77% +4.99% +4.24%
EBITDA Margin
-351.42% -193.48% -249.79% -180.03%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 18.25
Number of Ratings 3 Current Quarters Estimate -3.445
FY Report Date 03 / 2026 Current Year's Estimate -9.997
Last Quarter’s Earnings -1.97 Median PE on CY Estimate N/A
Year Ago Earnings -8.553 Next Fiscal Year Estimate -9.715
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 2 2 3 2
Mean Estimate -3.45 -3.23 -10.00 -9.72
High Estimates -1.22 -0.93 -2.91 -1.87
Low Estimate -5.67 -5.53 -21.65 -17.56
Coefficient of Variance -91.34 -100.70 -101.74 -114.20

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 3
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Dariohealth - DRIO

Date Name Shares Transaction Value
Sep 16, 2025 Dennis M. McGrath Director 27,737 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 16, 2025 Yoav Shaked Director 32,810 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 16, 2025 Hila Karah Director 30,965 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 16, 2025 Dennis Albert Matheis Director 27,631 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 16, 2025 Erez Raphael Chief Executive Officer; Director 156,853 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 16, 2025 Chen Franco-Yehuda Chief Financial Officer 30,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 Jon H. Kaplan Director 111,574 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Dariohealth in the News